Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test.
OBJECTIVE
The present study was designed to determine the eradication rate of 10 day sequential therapy in genotypic clarithromycin-resistant Helicobacter pylori group identified by molecular polymerase chain reaction (PCR) detection in Thai patients.


METHODS
Between May 2007 and June 2010, patients who had undergone gastroscopic examination at the King Chulalongkorn Memorial Hospital, for dyspeptic symptoms were recruited. Two biopsy samples from gastric antrum were obtained, one for rapid urease test and another for PCR. PCR-sequencing was performed to determine point mutations in 23S rRNA gene. Patients received 10 day sequential therapy consisting of lanzoprazole 30 mg and amoxicillin 1 g twice daily for 5 days followed by lanzoprazole 30 mg, clarithromycin 500 mg and nitroimidazole 500 mg twice daily for the remaining 5 days. Urea breath test (UBT) was performed to assess eradication therapy.


RESULTS
A total of 151 patients (mean age 52.7 years, 75 males and 76 females) were recruited in this study. All patients completed sequential therapy without significant side effects. Point mutations at A2143G and A2142G were detected in 17 patients (11.3%). Overall eradication rate was 94%. The eradication rate in the group with point mutation was significantly lower than the eradication rate in the group without point mutation (64.7% vs 97.8%; odds ratio = 19.6 and 95% confidence interval = 4.3-88.8; P < 0.0001).


CONCLUSIONS
Genotypic clarithromycin resistance was detected in only 11.3% of H. pylori infections in Thailand. Sequential therapy is highly effective in clarithromycin-sensitive but is less effective in clarithromycin-resistant H. pylori. PCR-molecular test could be a useful tool to identify antimicrobial resistance for optimizing an eradication regimen.
Division of Gastroenterology, Department of Internal Medicine, Chulalongkorn University Hospital, Bangkok, Thailand. vmahachai@gmail.com
Varocha
V
Mahachai
Nathavut
N
Sirimontaporn
Somying
S
Tumwasorn
Duangporn
D
Thong-Ngam
Ratha-Korn
RK
Vilaichone
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001706:Biopsy; D001944:Breath Tests; D016009:Chi-Square Distribution; D017291:Clarithromycin / Q000008:administration & dosage* / Q000009:adverse effects; D004269:DNA, Bacterial / Q000032:analysis; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005773:Gastroscopy; D005838:Genotype; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000008:administration & dosage; D016017:Odds Ratio; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D021521:Ribotyping / Q000379:methods*; D018570:Risk Assessment; D012307:Risk Factors; D013785:Thailand; D013997:Time Factors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D009593:Nitroimidazoles; D054328:Proton Pump Inhibitors; D012338:RNA, Ribosomal, 23S; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin